Bone Biologics is a publicly traded company based in Boston, MA and is focused on developing and marketing orthobiologic products. Our proprietary platform technology is NELL-1, a recombinant human protein growth factor that is essential for normal bone development. Our lead product is a NELL-1 based bone graft substitute for spine fusion, targeting the rapidly growing orthobiologics market. Our goal is to offer patients superior safety with uncompromising efficacy relative to existing technologies. NELL-1 provides specific targeted regulation over bone regeneration in the presence of targeted osteogenic cells, as both demonstrated in the lab and through the use of animal testing, unlike any other current therapy. It has been shown not to form bone when applied to non-osteogenic cells such as myoblasts (a type of embryonic progenitor cell that differentiates to give rise to muscle cells) nor does it induce adipogenesis (the formation of fat that can occur within the bone matrix often exhibited as cysts) that results in weaker bone.
Our mission is to utilize the power of NELL-1 to improve clinical outcomes and reduce total health care delivery costs associated with spinal fusion. Bone Biologics is focused on bone repair and regeneration applications and is committed to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.
The Bone Biologics leadership team consists of some of the top leaders and innovators of orthobiologics in regenerative medicine. Not only does our leadership provide strategic oversight of the Company, they contribute to the collective advancement of the industry. This leadership is instrumental in fulfilling our mission to improve clinical outcomes and reduce health care delivery costs associated with lumbar spinal fusion.
While Bone Biologics has chosen to focus its initial product development efforts in spinal fusion, we believe that this regenerative medicine technology has potential in the broader fields of bone regeneration and repair including osteoporosis, chondrocytes and applications using mesenchymal stem cells.
New Strategy Aims to Enhance Efficacy and Safety of Bone Repair Treatment
PHILADELPHIA, (January 6, 2016) – Bone morphogenetic protein-2 (BMP2) is used clinically to promote bone repair. However, the high BMP2 concentrations required to stimulate bone growth in humans may produce life-threatening adverse effects such as cervical swelling in spinal fusion procedures, a problem that prompted an FDA warning in 2008. Now, a team of clinicians and engineers has shown that adding the protein kinase C-binding protein NELL-1 (Nel-like molecule-1) to BMP2 therapy may allow clinicians to achieve better results at lower – and safer – BMP2 doses. Their findings are reported in The American Journal of Pathology.
BMP2 is an FDA-approved osteoinductive growth factor used for spinal fusions and treatment of skeletal defects. An important limitation of BMP2 treatment is the formation of abnormal, adipose-filled, poor-quality bone that extends beyond the proper boundaries of the defect. Adverse effects, such as cervical swelling, ectopic bone formation, osteoclastogenesis, and inconsistent bone formation, may occur at high dosages. Therefore, the practical goals of treatment are to produce good-quality bone (osteogenesis) and to inhibit production of the abnormal adipose cell intruders (adipogenesis).
“In this study, we show both NELL-1 inhibition of BMP2-induced adipogenesis and NELL-1 + BMP2 synergy in bone formation. Overall, NELL-1 together with BMP2 forms bone of better quality than BMP2 alone. The combination treatment of NELL-1 with BMP2 may be particularly valuable in clinical scenarios in which bone regeneration is impaired, such as with steroid treatment or osteoporosis,” noted Dr. Chia Soo, MD, FACS, Vice Chair in Research in the Division of Plastic and Reconstructive Surgery and the Research Director of the Operation Mend of the UCLA School of Medicine.
Investigators evaluated NELL-1 and BMP2 in vitro and in vivo in animals. Using a femoral segmental defect model, in which a section of a rat’s femur is surgically removed, the investigators studied bone regrowth 8 weeks after surgery.
Histological analysis of untreated controls showed fibrous tissue growth within the surgical cavity, with no connection formed between the surgically-separated ends of the femoral bone and no evidence of trabecular bone formation (the connective tissue strands that provide a framework for regeneration). With BMP2 treatment, the fractured ends became connected, but the newly formed bone contained adipose tissue interspersed with sparse trabecular bone, which grew beyond the original margins. In contrast, the combination of NELL-1 + BMP2 produced tightly woven trabecular bone that remained largely within the area of the defect.
Other tests confirmed that adipose cells were evident in the BMP2-treated cavities but not in those administered NELL-1 + BMP2. NELL-1 also inhibited BMP2-stimulated adipogenesis in vitro from progenitor cells of multiple species. The investigators used a variety of advanced techniques to show that NELL-1 + BMP2 significantly increased all markers of bone growth relative to either treatment alone, including tests performed on human bone marrow stromal cells. The authors suggest that NELL-1 encourages cells early in their development to become osteogenic, rather than adipogenic.
NELL-1 regulation of BMP2-induced osteogenesis and adipogenesis may occur through activation of canonical (β-catenin-dependent) Wnt signaling, explained Aaron W. James, MD, Bone Pathologist in the Department of Pathology of the UCLA School of Medicine, who added that, in general, increased Wnt signaling steers cells toward osteogenesis rather than adipogenesis. (Wnt signaling via Wnt proteins allows cells to communicate and is thought to play a role in the regulation of mesenchymal stem cell maintenance and differentiation during bone development and maturity.)
“The ability of NELL-1 to activate Wnt signaling suggests potential utility in conditions such as osteoporosis, where the balance between osteogenesis versus adipogenesis and the balance between bone deposition versus resorption is perturbed to favor bone loss,” said Dr. Kang Ting, DMD, DMedSc, Professor and Chair in the Division of Growth and Development of the UCLA School of Dentistry, and Professor in UCLA’s Departments of Bioengineering and Orthopaedic Surgery. He added that these findings uncover new treatment possibilities for osteoporosis, such as the use of antibodies against endogenous Wnt pathway inhibitors, two of which are currently in Phase 3 clinical trials.
Treatments to promote bone development may be valuable for those with weakened bones, whether due to osteoporosis, cancer, medications, surgery, or trauma. Recombinant BMP is FDA-approved for use in limited patient populations such as patients with degenerative disc disease needing lumbar spine fusion, stabilized acute open tibial shaft fractures, and inability to undergo a successful autograft. In future work, the investigators hope their findings will enable a reduction of the currently-required clinical dose of BMP2 and, subsequently, result in fewer adverse events.
# # #
Notes for Editors
“Novel Wnt regulator Nel-like molecule-1 antagonizes adipogenesis and augments osteogenesis induced by bone morphogenetic protein-2,” by Jia Shen, PhD, Aaron W. James, MD, Xinli Zhang, MD, PhD, Shen Pang, PhD, Janette N. Zara, MD, Greg Asatrian, BS, Michael Chiang, BDS, Min Lee, PhD, Kevork Khadarian, BS, Alan Nguyen, BS, Kevin S. Lee, BS, Ronald K. Siu, MS, Sotirios Tetradis, DDS, PhD,Kang Ting, DMD, DMedSc, Chia Soo, MD, FACS (DOI: http://dx.doi.org/10.1016/j.ajpath.2015.10.011).This article appears online ahead of The American Journal of Pathology, Volume 186, Issue 2 (February 2016) published by Elsevier.
Full text of this study is available to credentialed journalists upon request; contact Eileen Leahy at 732-238-3628 or firstname.lastname@example.org. Journalists wishing to interview the authors should contact Brianna Aldrich at 310-206-0835 or email@example.com.
This research was supported by the CIRM Early Translational II Research Award TR2-01821, NIH/NIAMS (grants RO1 AR066782-01, AR068835-01A1, AR061399-01A1, K08 AR068316), UCLA /NIH CTSI grant UL1TR000124, National Aeronautical and Space Administration (“NASA”) GA-2014-154, Eli & Edythe Broad Center of Regenerative Medicine, and Stem Cell Research at UCLA Innovation Award. R.K.S. and A.W.J. were supported by T32 training fellowships (5T32DE007296-14). J.N.Z. was supported by a CIRM training fellowship (TG2-01169).
About The American Journal of Pathology
The American Journal of Pathology (http://ajp.amjpathol.org), official journal of the American Society for Investigative Pathology, seeks to publish high-quality, original papers on the cellular and molecular biology of disease. The editors accept manuscripts that advance basic and translational knowledge of the pathogenesis, classification, diagnosis, and mechanisms of disease, without preference for a specific analytic method. High priority is given to studies on human disease and relevant experimental models using cellular, molecular, animal, biological, chemical, and immunological approaches in conjunction with morphology.
The leading global forum for reporting quality original research on cellular and molecular mechanisms of disease, The American Journal of Pathology is the most highly cited journal in Pathology – close to 40,000 cites in 2014 – with an Impact Factor of 4.591 and Eigen factor of 0.06689 according to the 2014 Journal Citation Reports®, Thomson Reuters, 2015, and an h-index of 217 according to the 2014 SCImago Journal and Country Rank.
Elsevier (www.elsevier.com) is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them Science Direct (www.sciencedirect.com), Scopus (www.scopus.com), Elsevier Research Intelligence (www.elsevier.com/research-intelligence), and Clinical Key (www.clinicalkey.com) — and publishes over 2,500 journals, including The Lancet (www.thelancet.com) and Cell (www.cell.com), and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group plc (www.relxgroup.com), a world-leading provider of information solutions for professional customers across industries. www.elsevier.com
For information regarding our company and/or products, please complete the form below.